期刊
ASIAN JOURNAL OF PSYCHIATRY
卷 57, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ajp.2020.102512
关键词
Attention deficit hyperactivity disorder; Pediatric; Prevalence; Prescription; Guanfacine
类别
资金
- Ministry of Education, Culture, Sports, Science and Technology, Japan [19K07213]
- Grants-in-Aid for Scientific Research [19K07213] Funding Source: KAKEN
The study revealed changes in prescription trends of ADHD medications for pediatric outpatients in Japan from 2012 to 2018, with a decrease in the prescription rates of methylphenidate-OROS and atomoxetine, while an increase in the prescription rate of guanfacine.
We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据